{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:42:30Z","timestamp":1771656150688,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007967","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000}}],"reference-count":129,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007967.pub2","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T22:10:13Z","timestamp":1326924613000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Acetylcholinesterase inhibitors for schizophrenia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Jasvinder","family":"Singh","sequence":"first","affiliation":[{"name":"Humber NHS Foundation Trust; Department of Psychological Medicine; 220-236 Anlaby Road Hull UK HU3 2RT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalpreet","family":"Kour","sequence":"additional","affiliation":[{"name":"Leeds Partnership Foundation Trust; St Marys House St Marys Road Leeds West Yorkshire UK LS 7 3JX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh B","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Leeds Partnership Foundation NHS Trust; CMHT; Aire Court Lingwell Grove Leeds UK LS10 4BS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD007967.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.pnpbp.2008.08.001","article-title":"A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0002|cit2","first-page":"422","article-title":"Galantamine does not significantly effect positive or negative symptoms in patients with schizophrenia","volume":"33","author":"Boggs","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0003|cit3","unstructured":"Boggs DL Conley RR Nelson MW Feldman S Ball P McMohan RP Buchanan RW Galantamine does not significantly effect positive or negative symptoms in with schizophrenia Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA 2007"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0004|cit4","first-page":"424","article-title":"Galantamine for the treatment of cognitive impairments in patients with schizophrenia","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","article-title":"Galantamine for the treatment of cognitive impairments in people with schizophrenia","volume":"165","author":"Buchanan","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0007|cit6","unstructured":"Caroff SN Treatment of tardive dyskinesia with galantamine http:\/\/www.clinicaltrials.gov 2005"},{"issue":"3","key":"10.1002\/14651858.CD007967.pub2-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial","volume":"68","author":"Caroff","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007967.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1185\/030079906X167372","article-title":"Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits","volume":"23","author":"Chouinard","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD007967.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.pnpbp.2006.02.009","article-title":"Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial","volume":"30","author":"Guillem","year":"2006","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD007967.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2007.12.491","article-title":"High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia","volume":"102","author":"Dyer","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.WNF.0000240940.67241.F6","article-title":"Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study","volume":"30","author":"Fagerlund","year":"2007","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-005-2235-1","article-title":"Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial","volume":"181","author":"Freudenreich","year":"2005","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD007967.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biological Psychiatry"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD007967.pub2-BIB0014|cit14","first-page":"9","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"53","author":"Friedman","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0015|cit15","unstructured":"Friedman JI Adler DN Howanitz E Temporini H Harvey PD Davis KL Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"issue":"1, 2","key":"10.1002\/14651858.CD007967.pub2-BIB0016|cit16","first-page":"228","article-title":"Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia","volume":"49","author":"Friedman","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD007967.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","article-title":"Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial","volume":"33","author":"Keefe","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0018|cit18","first-page":"490","article-title":"A 12 week, double - blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia","volume":"31","author":"Kim","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0019|cit19","unstructured":"Kim YH Lee BJ A 12 week, double-blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt 2005"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0269881106070996","article-title":"A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia","volume":"21","author":"Lee","year":"2007","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD007967.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/13546800701307263","article-title":"No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia","volume":"12","author":"Kohler","year":"2007","journal-title":"Cognitive Neuropsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0022|cit22","first-page":"10","article-title":"A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for cognitive impairments in chronic schizophrenia","volume":"3","author":"Lee","year":"2005","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e3280117feb","article-title":"A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia","volume":"22","author":"Lee","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD007967.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1076\/neur.9.3.274.15563","article-title":"Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study","volume":"9","author":"Nahas","year":"2003","journal-title":"Neurocase"},{"issue":"6","key":"10.1002\/14651858.CD007967.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone","volume":"60","author":"Schubert","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0026|cit26","first-page":"503","article-title":"Cognitive improvement in schizophrenia and schizoaffective disorder by augmentation of risperidone with galantamine","volume":"31","author":"Schubert","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.jcp.0000169267.36797.76","article-title":"Effects of rivastigmine on sustained attention in schizophrenia: an fMRI study","volume":"25","author":"Aasen","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0028|cit28","first-page":"140","article-title":"Enhanced attention with rivastigmine in schizophrenia: an fmri study","volume":"67","author":"Aasen","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neuroimage.2005.08.013","article-title":"Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study","volume":"29","author":"Kumari","year":"2006","journal-title":"Neuroimage"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007967.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/S0924-977X(04)80344-4","article-title":"Neural correlates of rivastigmine treatment in schizophrenia: an fMRI study","volume":"14","author":"Kumari","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0035|cit31","unstructured":"Sharma T Cognitive enhancement with revistagmine in schizophrenia National Research Register 2002"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0032|cit32","first-page":"208","article-title":"A placebo-controlled double-blind investigation of cognitive effects of rivastigmine in schizophrenia","volume":"67","author":"Sharma","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007967.pub2-BIB0031|cit33","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S0924-977X(04)80339-0","article-title":"A placebo-controlled double-blind investigation of cognitive effects of rivastigmine in schizophrenia","volume":"14","author":"Sharma","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0033|cit34","unstructured":"Sharma T Kumari V Adjunctive rivastigmine for people with schizophrenia who have cognitive impairment Stanley Foundation Research Programs 2000"},{"issue":"1-3","key":"10.1002\/14651858.CD007967.pub2-BIB0034|cit35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2006.03.037","article-title":"Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation","volume":"85","author":"Sharma","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S1461145703004024","article-title":"A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia","volume":"7","author":"Tugal","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0037|cit37","first-page":"S294","article-title":"A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for the cognitive impairment of schizophrenia","volume":"13","author":"Tugal","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/S0924-977X(03)92110-9","article-title":"Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia","volume":"13","author":"Tuma","year":"2003","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0039|cit39","unstructured":"Tuma I Lenderova Z Zemanova M Kadlecova E Perez M Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia Proceedings of the16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic 2003"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00431649","article-title":"Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion","volume":"72","author":"Davis","year":"1981","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD007967.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1176\/ajp.138.8.1078","article-title":"Physostigmine and lithium response in the schizophrenias","volume":"138","author":"Edelstein","year":"1981","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/ajp.130.2.141","article-title":"Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study","volume":"130","author":"El-Yousef","year":"1973","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.140.12.1629","article-title":"The use of tacrine for tardive dyskinesia","volume":"140","author":"Ingram","year":"1983","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0044|cit44","first-page":"113","article-title":"The elicitation of psychotic symptomatology by methylphenidate","volume-title":"Psychopathology and Psychopharmacology","author":"Janowsky","year":"1973"},{"issue":"12","key":"10.1002\/14651858.CD007967.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/ajp.130.12.1370","article-title":"Antagonistic effects of physostigmine and methylphenidate in man","volume":"130","author":"Janowsky","year":"1973","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archpsyc.1973.01750340072012","article-title":"Parasympathetic suppression of manic symptoms by physostigmine","volume":"28","author":"Janowsky","year":"1973","journal-title":"Archives of General Psychiatry"},{"issue":"1, 2","key":"10.1002\/14651858.CD007967.pub2-BIB0047|cit47","first-page":"216","article-title":"Effects of antipsychotics and other agents on prepulse inhibition of the startle response (ppi)","volume":"49","author":"Kristiansen","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00004714-198808000-00004","article-title":"Pharmacologic characterization of tardive dyskinesia","volume":"8","author":"Lieberman","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD007967.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1041610205003017","article-title":"Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study","volume":"18","author":"Mazeh","year":"2006","journal-title":"International Psychogeriatrics"},{"issue":"10","key":"10.1002\/14651858.CD007967.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1176\/ajp.137.10.1202","article-title":"Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes","volume":"137","author":"Moore","year":"1980","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0051|cit51","unstructured":"NCT00566735 The use of galantamine HBr (reminyl) in electroconvulsive therapy: impact on mood and cognitive functioning http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0052|cit52","unstructured":"Okereke CS Kumar D Cullen EI Pratt RD Hahne WF Safety and pharmacokinetics profile of concurrent donepezil hcl and levodopa\/carbidopa Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007967.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S0924-977X(04)80026-9","article-title":"Rivastigmine therapy for memory deficits in schizophrenia patients receiving electroconvulsive treatment","volume":"14","author":"Ophir","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0054|cit54","unstructured":"Pesco-Koplowitz L Parier J-L Zhao Q Heron J Pharmacokinetics of risperidone\/donepezil combination Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico 1999"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"167S","DOI":"10.1016\/S0006-3223(00)00818-0","article-title":"Pharmacokinetics of risperidone\/donepezil combination","volume":"47","author":"Pesco-Koplowitz","year":"2000","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004714-198107000-00003","article-title":"Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates","volume":"1","author":"Risch","year":"1981","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/neucas\/7.2.105","article-title":"A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates","volume":"7","author":"Risch","year":"2001","journal-title":"Neurocase"},{"issue":"5","key":"10.1002\/14651858.CD007967.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/hup.595","article-title":"Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study","volume":"19","author":"Stryjer","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD007967.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1176\/ajp.134.7.769","article-title":"Cholinergic influences in tardive dyskinesia","volume":"134","author":"Tamminga","year":"1977","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0060|cit60","unstructured":"Fleming K Potkin SG A 26-week, double-blind, placebo-controlled antipsychotic augmentation study of memantine plus donepezil in the treatment of 60 outpatients with schizophrenia Stanley Foundation Research Programs 2003"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0061|cit61","unstructured":"Hussain MZ Chaudhry ZA Rivastigmine and galantamine treatment for schizophrenic cognitive impairment Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0062|cit62","unstructured":"Hussain MZ Chaudhry ZA Rivastigmine and galantamine treatment of schizophrenic cognitive impairment Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0063|cit63","unstructured":"Kelleher JP Shinnar MR Olshanskiy V Malhotra A Kane J Sonnenberg M Lascher S Galantamine treatment of comorbid nicotine dependence in patients with schizophrenia or schizoaffective disorder Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA 2008"},{"issue":"6","key":"10.1002\/14651858.CD007967.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0028-1094395","article-title":"Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)","volume":"6","author":"Modestin","year":"1973","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0065|cit65","unstructured":"Ball MP Buchanan RW Adjunctive galantamine for treatment of cognitive impairments in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0066|cit66","unstructured":"Evins AE Effect of nicotine agonist galantamine added to high potency medications for cognitive function in patients with schizophrenia and schizoaffective disorder http:\/\/www.clinicaltrials.gov 2006"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0067|cit67","unstructured":"Gaskins BL Deutsch SI Schwartz BL Rosse RB Schooler N Interventions to test the alpha7 nicotinic receptor model in schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0068|cit68","unstructured":"George TP Sacco KA Vessicchio J Galantamine for cognitive deficits in schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0069|cit69","unstructured":"Glenthoj B Pharmacological treatment of cognitive deficits in schizophrenic patients: the effects of central cholinergic augmentation on cognitive deficits and psychopathology http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0070|cit70","unstructured":"Johnson & Johnson Pharmaceutical Research and Development A study of galantamine hbr as an adjunctive treatment to atypical antipsychotic medications in outpatients with schizophrenia and associated cognitive deficits http:\/\/www.clinicaltrials.gov 2004"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0071|cit71","unstructured":"Nachshoni T Kupchik M Donepezil double blind trial for ECT memory dysfunction http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"22","author":"Addington","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD007967.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0074|cit74","volume-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0075|cit75","first-page":"53","article-title":"Scale for the assessment of negative symptoms (SANS)","volume":"7","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1037\/1040-3590.8.2.145","article-title":"Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity","volume":"8","author":"Benedict","year":"1996","journal-title":"Psychological Assessment"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007967.pub2-BIB0080|cit80","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13854049108403297","article-title":"The hopkins verbal learning test: Development of a new memory test with six equivalent forms","volume":"5","author":"Brandt","year":"1991","journal-title":"Clinical Neuropsychology"},{"issue":"330","key":"10.1002\/14651858.CD007967.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"10","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007967.pub2-BIB0084|cit84","first-page":"89","article-title":"Clinical review of risperidone","volume":"38","author":"Chouinard","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0085|cit85","volume-title":"Conners\u00ea Continuous Performance Test II: Computer Program for Windows Technical Guide and Software Manual","author":"Conners","year":"2000"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"Craig JC Webster AC Loy C How long should treatments be continued? BMJ 2010 c4102","DOI":"10.1136\/bmj.c4102"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0087|cit87","unstructured":"Deeks JJ Issues in the selection of a summary statistic for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa Cape Town Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD007967.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0090|cit90","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0093|cit93","unstructured":"Gelenberg AJ Levy P Manoukian SV Maintaining metabolic and cardiovascular health in patients with schizophrenia: perspectives in long-term care http:\/\/cme.medscape.com\/viewarticle\/491506"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0095|cit95","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0096|cit96","first-page":"21","article-title":"Rating depressive patients","volume":"41","author":"Hamilton","year":"1980","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0097|cit97","volume-title":"Wisconsin Card Sorting Test Manual: Revised and Expanded, Psychological Assessment Resources","author":"Heaton","year":"1993"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0099|cit99","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000904","article-title":"Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine. Monograph Supplement"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0102|cit102","first-page":"300","article-title":"A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients","volume":"15","author":"Kang","year":"1997","journal-title":"Korean Neurological Association"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0103|cit103","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"Positive and negative syndrome scale (PANSS) manual","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0105|cit105","volume-title":"Instruction Manual for the Adult Neuropsychology Test Battery","author":"Matthews","year":"1964"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006625.pub2","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"50","key":"10.1002\/14651858.CD007967.pub2-BIB0107|cit107","first-page":"s46","article-title":"Cognition as an outcome measure in schizophrenia","volume":"191","author":"Michael","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD007967.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0110|cit110","volume-title":"Rey Complex Figure Test and Recognition Trial: Professional Manual","author":"Meyers","year":"1995"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0111|cit111","first-page":"385","article-title":"Verbal fluency as a function of a measure of verbalintelligence and in relation to different types of cerebral pathology","volume":"8","author":"Miller","year":"1984","journal-title":"British Journal of Clinical Psychology"},{"issue":"9426","key":"10.1002\/14651858.CD007967.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Randolph C Repeatable battery for the assessment of neuropsychological status Psychological Corporation 1998","DOI":"10.1037\/t15149-000"},{"issue":"8","key":"10.1002\/14651858.CD007967.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrpyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"7400","key":"10.1002\/14651858.CD007967.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.326.7400.1202","article-title":"Medical journals and pharmaceutical companies: uneasy bedfellows","volume":"326","author":"Smith","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0119|cit119","first-page":"469","article-title":"Psychopharmacology of reward and drugs of abuse","volume-title":"Essential Psychopharmacology","author":"Stahl","year":"2000"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions","volume":"18","author":"Stroop","year":"1935","journal-title":"Journal of Experimental Psychology"},{"issue":"2","key":"10.1002\/14651858.CD007967.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail making test A and B: Normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Archives of Clinical Neuropsychology"},{"issue":"5","key":"10.1002\/14651858.CD007967.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0123|cit123","volume-title":"Wechsler Adult Intelligence Scale- Administration And Scoring Manual","author":"Wechsler","year":"1997"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0124|cit124","volume-title":"Wechsler Memory Scale- Administration and Scoring Manual","author":"Wechsler","year":"1997"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.159.5.838","article-title":"Test and retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia","volume":"159","author":"Wilk","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s001090050250","article-title":"Cholinergic strategies for alzheimer's disease","volume":"76","author":"Winkler","year":"1998","journal-title":"Journal of Molecular Medicine"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"Drug Bank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Research"},{"key":"10.1002\/14651858.CD007967.pub2-BIB0128|cit128","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"},{"issue":"1","key":"10.1002\/14651858.CD007967.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.npp.1380235","article-title":"Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia","volume":"12","author":"Yeomans","year":"1995","journal-title":"Neuropsychopharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007967.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:16:02Z","timestamp":1721661362000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007967.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":129,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007967.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}